The CVR is an option, and Lilly holds it

Lilly owes effort on TRD alone, and no holder can force it. A European Phase 3 can still trigger the first $1.00.

Lead Story

The CVR in Lilly's AtaiBeckley deal obliges Lilly to try on one indication out of three. And no holder can force it to.

Every headline printed $3.8 billion. We read Annex III, the agreement itself, because a contract says what a buyer will actually do.

The CVR pays on three indications. Lilly owes effort on one: TRD. On MDD and GAD it owes no effort, and on TRD the agreement bars holders from specific performance and supersedes any implied duty of good faith.

On the economics, it's hard to blame Lilly. Both programmes ran Phase 2 in TRD, and neither has tested MDD or GAD. BPL-003 also ran a Phase 2 in alcohol use disorder. Approval there would pay holders nothing.

"Up to $2.50" is not the same as "owed $2.50." Lilly bought the right to decide, not a commitment to develop. Anyone modelling a GH001 or COMP360 exit is one control premium short.

Read the full Exhibit 01, two pages, with every section reference.

The signed copy was never filed

AtaiBeckley filed Form 15-12G on 21 September. It has suspended its SEC reporting, and the signed CVR agreement was never filed. What holders can read is the form attached to the merger agreement, which is what Exhibit 01 uses. Every CVR holder is now relying on the form, not the signed copy, to know what they own.

Deal tape

No new deal this week. The ledger grew anyway. Otsuka/Transcend and AbbVie's 2024 Gilgamesh option are in, and our AbbVie/Gilgamesh row was wrong on three fields: upfront, announcement date and close date. Corrected against the 10-K.

Europe: checked, nothing new

CHMP sat 14 to 17 September. No psychedelic came near it. The two European trials that moved this week are both academic: a Swedish ketamine study and a French psilocybin one. Compass issued eight releases in September and named neither the EMA nor the MHRA, while COMP006 has patients in ten European countries. Our read: Europe runs the trials. Nobody files here.

Failed checks, not zeros

Our Compass monitor reported zero items this month. There were eight. A Cloudflare block returned nothing and the tool read it as silence. We caught it by hand, and until it's fixed Compass gets checked manually every week. Otsuka's Japanese filings are unread, so Transcend stays at reported, not verified.

Ledger

Eleven carried in; this issue makes the twelfth. Two scored, both hits. Issue 3 resolves on 30 September. It calls AtaiBeckley reporting a first BPL-003 Phase 3 patient dosed in Q3. AtaiBeckley has suspended its reporting. As of today there is no BPL-003 Phase 3 registered on ClinicalTrials.gov under any sponsor. The call resolves on an announcement, not a registry, so this is evidence, not a score. It scores in Issue 17.

The call

No Lilly-sponsored Phase 3 trial of VLS-01 in major depressive disorder is registered on ClinicalTrials.gov or CTIS by 30 June 2027. Our read of CVR Section 4.3(a)(i), the VLS Indication Exclusion, which leaves Lilly no efforts obligation for MDD or GAD.

Falsifier: a Lilly-sponsored VLS-01 Phase 3 in MDD registered on ClinicalTrials.gov or CTIS by 30 June 2027. Registration is public before first dosing. First dosing is the contractual trigger.

Resolves 2027-06-30. Logged as call 15 on the ledger and printed in Exhibit 01, which is the published source for this call.

Corrections

Correction to Issue 10. We said ReConnection-2 moved from about 300 to about 230 participants in the August filing. The numbers were right. The date was not: AtaiBeckley first disclosed the change on 12 May, in its Q1 release.

Correction to Issue 14. The email said the sixth brenipatide trial had 29 sites across Germany, France and the Netherlands. The CTIS record lists four countries: France 10, Germany 9, the Netherlands 6 and Poland 4. The site total was right. Poland was missing.